<- Go Home
Vor Biopharma Inc.
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren’s disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Market Cap
$862.1M
Volume
925.8K
Cash and Equivalents
$169.9M
EBITDA
-$341.7M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$65.80
52 Week Low
$3.06
Dividend
N/A
Price / Book Value
-5.73
Price / Earnings
-0.34
Price / Tangible Book Value
-5.73
Enterprise Value
$373.5M
Enterprise Value / EBITDA
-1.15
Operating Income
-$343.8M
Return on Equity
2093.72%
Return on Assets
-69.76
Cash and Short Term Investments
$491.5M
Debt
$2.9M
Equity
-$150.4M
Revenue
N/A
Unlevered FCF
-$195.8M
Sector
Biotechnology
Category
N/A